We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Antigen Microarray Aids Diagnosis of Autoimmune Diseases

By Biotechdaily staff writers
Posted on 22 May 2002
A new diagnostic system for autoimmune diseases is based on an antigen microarray, which consists of glass slides dotted with thousands of proteins and other molecules that are often attacked in autoimmune diseases. More...
The microarray system, which is the result of research conducted at the Stanford University Medical Center (Stanford, CA, USA), is described in the March 2002 issue of Nature Medicine.

The antigen microarray assay allows the laboratory to screen a patient's sample for hundreds of antibodies simultaneously. "Right now clinicians test each antigen separately, and each one can take weeks,” said P.J. Utz, M.D., senior author of the study. These arrays could enable a clinician to diagnose the disease on the first visit.”

To use the microarray, doctors draw a blood sample from the patient and incubate it on the array. Those antibodies that recognize molecules on the array will attach and remain bound to them. Fluorescent molecules are added to detect the antibodies, creating colored spots on the slide. A computer then counts the spots to see which antigens the immune system recognized.

Most healthy people do not have antibodies that recognize most of antigens on the array. Diabetics, however, may produce arrays with spots corresponding to pancreas cell proteins, and people with rheumatoid arthritis produce spots that correspond to molecules found in the joints. Microarrays will also help determine who is at future risk of developing a disease because autoantibodies may be formed years before signs of illness appear.

"Even if the patients don't have the disease now, such microarrays may be able to predict which patients are most likely to develop the disease in the next five years,” says William Robinson, lead author of the study. "In the future, it may become possible to identify individuals at higher risk, such as those with a family history of autoimmune disease, so they can begin preventive therapy.”




Related Links:
Stanford University

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Aspiration System
VACUSAFE
New
Hematology Consumables
Bioblood Devices
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.